查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1834097

隱球菌病市場（按藥物類別、適應症、給藥途徑、最終用戶和分銷管道分類）—2025-2032 年全球預測

Cryptococcosis Market by Drug Class, Indication, Route Of Administration, End User, Distribution Channel - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 188 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年隱球菌病市場規模將成長至 116.6 億美元，複合年成長率為 7.87%。

主要市場統計數據
基準年2024年 63.5億美元
預計2025年 68.7億美元
預測年份：2032年 116.6億美元
複合年成長率（%） 7.87%

隱球菌病護理的臨床複雜性、診斷挑戰、治療途徑和系統級優先事項的權威介紹。

隱球菌病仍然是一種複雜的侵襲性真菌疾病，對免疫力缺乏人群的影響尤其嚴重，其診斷的模糊性和治療的複雜性也給醫療保健系統帶來了挑戰。臨床醫師會遇到各種各樣的病例，從亞急性肺部感染到危及生命的隱球菌腦膜炎，而病患病情的多樣性也使得及時介入變得複雜。實驗室確診通常需要培養、抗原檢測和神經影像學檢查，儘管在可控環境下已有成熟的抗真菌藥物，但延遲識別仍會增加發病率和死亡率。

從臨床照護、藥物研發和衛生政策相關人員的角度來看，隱球菌病需要對治療方式、給藥途徑和醫療服務環境有細緻的了解。治療模式涵蓋靜脈誘導治療、口服鞏固和維持治療，這給醫院藥房、門診和門診護理中心帶來了後勤負擔。同時，診斷和抗真菌藥物可近性的地區差異加劇了治療結果的不公平性。

本執行簡介概述了臨床挑戰，重點介紹了關鍵治療方法特點，並闡述了創新和營運變革如何顯著改善患者預後，為後續分析奠定了基礎。本簡介為深入探討變革性轉變、美國關稅相關壓力、細分市場主導的洞察、區域差異、公司動態以及為應對隱球菌病情勢的領導者提供的實用建議奠定了基礎。

診斷、治療創新、護理服務重新設計和管理舉措的進步如何改變整個醫療環境中的隱球菌病管理

隱球菌病領域正在經歷多重同步變化，這些變化正在重塑臨床醫生檢測、管理和預防重症疾病的方式。快速抗原檢測和照護現場技術的進步使得能夠更早發現隱球菌感染，從而更及時地啟動適當的抗真菌治療，並減少對長期經驗性治療的依賴。同時，影像學、分子檢測和整合電子健康記錄的改進也促進了對有中樞神經系統受累風險的患者進行更早的分診。

在治療方面，新型抗真菌化合物、最佳化的給藥方案以及針對宿主免疫反應的輔助治療策略正在推動該領域的新一輪關注。這些進展的驅動力在於轉化研究以及臨床醫生對更耐受、更符合邏輯的治療方案的需求，尤其是那些能夠減少長期住院和靜脈注射治療需求的方案。同時，抗真菌藥物抗藥性模式和現有藥物種類的日益多樣化，正在推動管理工作和投資，以增強製藥業的韌性。

醫療系統也在營運層面進行調整。重視門診輸液服務、整合診所監測計畫以及醫院與社區醫療服務提供者之間的合作，正在改變醫療服務的連續性。付款人和採購團隊越來越關注醫療總成本和以患者為中心的治療結果，鼓勵採取縮短住院時間和減少再入院的干涉措施。總而言之，這些轉型正在改變治療決策、供應鏈設計以及臨床實踐指南在多個醫療機構中的應用。

評估最近的關稅調整如何重塑藥品採購、供應鏈彈性、籌資策略以及關鍵抗真菌療法的獲取

2025年的政策格局將對隱球菌病供應鏈和採購實踐產生重大動態，因為關稅調整將影響進口原料藥、成品藥和臨床輔助產品的經濟效益。關鍵投入品關稅上調可能會增加藥廠和合約藥廠的到岸成本，給預算本已有限的醫院、診所和藥局的採購團隊帶來下游壓力。因此，更高的採購成本可能會加速優先考慮不依賴複雜無菌生產的口服產品，或將採購轉向擁有垂直整合生產能力的供應商，以減輕關稅的影響。

在營運方面，關稅帶來的成本壓力可能會加劇供應鏈的脆弱性，因為這會鼓勵靜脈注射藥物的囤積，增加對國內委託製造製造商的依賴，並導致通路重組。醫院可以透過修改處方集、協商延長供應合約以及實施更嚴格的用藥控制來應對，以保障高風險病患的用藥。這些應對措施通常與無菌製劑的監管要求和臨床需求交叉，以確保靜脈注射誘導療法的不間斷供應，因為靜脈誘導療法比口服藥物更難被替代。

監管機構和商業相關人員可能會採取緩解措施，以維持醫療服務的連續性。製造商可以考慮對原料藥進行再製造或採用替代籌資策略，重新評估關稅分類，並擴大區域製造地，以避免關稅的影響。付款人和採購專業人員可以更加重視基於價值的合約和批量採購安排，以平滑價格波動。衛生系統應預測採購週期，並擴大考慮地緣政治風險和關稅制度，並與供應夥伴密切合作，以確保可預測的採購管道。在這種環境下，將臨床優先順序與供應鏈敏捷性結合的策略規劃對於保護患者照護並有效管理關稅的累積影響至關重要。

跨藥物類別、臨床適應症、給藥途徑、護理環境和分銷管道的細分主導洞察，用於確定干涉措施的優先順序並最佳化護理的連續性

細分為評估隱球菌病治療途徑中的治療和操作優先順序提供了一個結構化的視角。藥物類別包括Azole、棘白菌素類、Polyenes和嘧啶類似物。Azole包括Fluconazole、Isavuconazole唑、Itraconazole、Posaconazole和Voriconazole，而棘白菌素類包括阿尼芬淨、Caspofungin和Micafungin。隱球菌腦膜炎、擴散性隱球菌病和肺隱球菌病的臨床策略因適應症而異，每種疾病都需要不同的診斷途徑、監測強度和治療持續時間，從而影響臨床決策和資源分配。

給藥途徑的差異，例如靜脈注射與口服，會影響營運考慮因素，例如住院床位利用率、門診病人輸液能力以及依從性支持的重要性。同樣，對最終用戶（門診護理中心、診所和醫院）進行細分，可以明確在哪些方面對就地檢驗、輸液基礎設施和臨床醫生教育的投資將產生最大影響。分銷管道細分（區分醫院藥房、線上藥房和零售藥房）突顯了不斷發展的採購和訪問模式。醫院藥房管理急性住院供應和無菌配藥，而線上和零售藥房在門診病人整合和維護階段發揮著越來越重要的作用，要求臨床處方工作流程和配藥物流之間具有互通性。

整合這些細分維度，可以明確哪些介入措施可以優先考慮，從而最佳化療效。例如，將藥物類別偏好與給藥途徑的實際情況相結合，可以減少不必要的住院治療；而將最終用戶與分銷管道相結合，則可以提高從引入到維持的醫療服務的連續性。這種細分主導的觀點，使相關人員能夠根據最重要的臨床場景和醫療服務提供環境，有針對性地投資於診斷、處方集管理和供應鏈重建。

區域醫療保健基礎設施、法律規範和製造地如何影響隱球菌病治療的可近性、治療實施和策略性投資

區域動態對臨床實踐、抗真菌藥物的可及性以及管理隱球菌病的運作能力有著重大影響。美洲的醫療保健系統在資源和基礎設施方面存在差異，既有先進診斷和住院管理能力的中心，也有面臨醫療服務障礙的農村和服務不足地區。這種地理差異性需要製定區域策略，將集中式專科護理與分散式診斷和門診管理能力相結合，以確保及時識別和治療不同人群。

歐洲、中東和非洲地區法律規範、採購機制和製造地各不相同，導致獲得基本抗真菌藥物和支持性治療的程度參差不齊。有些國家擁有強大的醫院系統，可以快速實施靜脈誘導治療，而有些國家則由於無菌製劑和某些藥物的取得有限，治療方案有限。因此，區域政策協調和診斷及輸液服務能力建構對於在不同醫療環境中實現治療結果標準化至關重要。

亞太地區疾病負擔高，製藥生產能力快速發展，報銷模式差異顯著。這些動態為創新分銷方式、官民合作關係以及減少對遠距供應籌資策略依賴的本地生產創造了機會。在所有地區，臨床指南、採購策略和供應鏈計劃之間的互通性對於確保公平及時且符合指南的隱球菌病治療至關重要。

關鍵的公司策略和夥伴關係動態著重於治療創新、無菌製造彈性、分銷多樣化和增值患者服務

隱球菌病生態系中的企業策略體現了治療開發創新與營運措施之間的平衡，以確保現有抗真菌藥物的可靠供應。製藥和生物技術公司正致力於完善新型化合物的研發管線並改善製劑，以減少對住院給藥的依賴。同時，成熟和學名藥藥製造商正在投資無菌生產能力和品質體系，以滿足誘導治療和維持治療的需求。

臨床研究機構、契約製造和專業經銷商之間的合作日益普遍，這有助於將臨床數據快速轉化為可用產品。各公司也正在多元化其分銷網路，以減少對單一供應商的依賴，並適應關稅和貿易中斷的影響。商業團隊優先考慮與醫院藥屋主任和綜合護理網路合作，以確保產品供應與臨床路徑和採購週期保持一致。

除了產品供應，競爭對手還透過提供患者支持計劃、口服維持治療依從性解決方案以及針對治療複雜隱球菌病例的臨床醫生的教育計劃等服務來脫穎而出。這些附加價值服務旨在最佳化患者預後，同時將治療方法融入緊密結合的護理路徑中。整體而言，企業活動正朝著兩個目標集中：推進簡化臨床管理的治療方法方案，以及加強供應和銷售管道，確保在不同醫療機構中實現持續的可及性。

針對製造商、醫療保健提供者和付款人可以採取的行動建議，以增強供應鏈彈性、簡化治療方法的交付並使獎勵與患者結果保持一致。

透過結合臨床、營運和商業性措施，業界領導者可以採取切實可行的措施來改善臨床療效，並確保抗真菌療法的可及性。製造商應優先投資於能夠實現更口服或更便捷給藥方案的製劑研究，同時透過擴大區域生產和合格供應商網路來降低貿易中斷帶來的風險。這種方法可以減少對單一原料藥的依賴，並提高靜脈注射和口服藥物產品的連續供應。

健康系統和醫院藥房應正式製定應急採購計劃，包括誘導藥物的戰略庫存政策以及以臨床共識為指導的快速替代機制。加強與門診輸液提供者以及零售或線上藥局的合作，將有助於從住院誘導治療順利過渡到門診維持治療。此外，臨床負責人應將快速隱球菌抗原檢測納入分診通訊協定，並採用標準化的集束化治療方案，以確保及早啟動適當的治療並持續進行追蹤。

支付者和政策制定者可以透過將報銷激勵措施與基於結果的指標獎勵來實現這一轉變，這些指標旨在獎勵縮短住院時間、減少再入院率以及遵守循證治療途徑。跨部門合作——製造商、支付方、醫療保健提供者和患者權益團體之間的合作——對於設計切合實際的採購框架、支持教育計畫以及維護抗真菌藥物有效性的實踐管理至關重要。透過針對供應鏈、醫療保健服務和報銷架構實施協調一致的行動，產業領導者可以顯著改善隱球菌病患者的治療可及性和療效。

採用嚴格的混合調查方法，結合文獻綜合、專家訪談、採購分析和情境評估，提供可行的臨床和商業性見解

本分析所採用的調查方法結合了結構化一手資料和二手資料的審查、專家訪談以及對臨床和商業主題的交叉檢驗。二手資料研究涵蓋同行評審文獻、臨床實踐指南、監管通知和臨床試驗註冊，以繪製治療概況、診斷方法和標準治療流程。這些資訊來源提供了必要的臨床背景，有助於解釋治療機制、安全性和給藥途徑的影響。

我們的主要研究包括對住院和門診治療隱球菌病的臨床醫生、醫院藥房負責人、採購專家以及負責生產和分銷的行業高管進行結構化訪談。這些訪談提供了關於供應鏈風險、處方決定因素以及實施誘導和維持治療的現實挑戰的實用觀點。此外，我們也整合了去識別化的醫院採購模式和診斷使用率指標，以便更好地了解通路動態和醫療環境壓力。

在資料整合過程中，我們優先考慮三角測量，以確保臨床發現與營運實際情況和供應鏈約束一致。分析技術包括定性訪談的主題分析、治療特徵與護理環境的交叉映射，以及在關稅變化等政策變化情境下的評估。這種混合方法提供了均衡且可操作的洞察，同時保持了資料來源和指南的透明度。

簡潔的總結性綜合強調了診斷、治療、供應彈性和協調激勵措施之間的獎勵，以改善隱球菌病的結果。

總而言之，隱球菌病帶來了持續的臨床挑戰，並交織著複雜的營運和商業考量。臨床醫生、製造商和醫療保健系統領導者必須確保及時獲得靜脈誘導治療和口服維持治療，同時應對診斷的多樣性、治療方案的複雜性以及不斷變化的政策環境。結合更快的診斷、簡化的治療方法和多樣化的供應鏈的策略性應對措施，對於改善療效和防止中斷至關重要。

治療細分、護理環境動態變化以及本地基礎設施互動凸顯了製定符合當地實際情況的客製化干涉措施的必要性。對即時診斷、門診輸液能力和製造冗餘的投資將透過促進符合指南的護理並減少可預防的併發症，帶來不成比例的效益。同樣重要的是，將商業和報銷模式與臨床目標相結合，以獎勵高價值護理。

最終，積極主動地重新設計護理路徑、加強醫護人員關係並追求循證創新的利益相關人員將最有可能減輕臨床負擔並確保持續獲得​​抗真菌療法。本報告中的見解將有助於指導這些策略選擇，並為將臨床證據轉化為行動提供實際的藍圖。

目錄

第1章：前言

第2章調查方法

第3章執行摘要

第4章 市場概況

第5章 市場洞察

  • 擴展針對抗藥性隱球菌菌株的下一代抗真菌療法
  • 在資源有限的地區引入快速即時診斷檢測方法，以便早期檢測隱球菌抗原
  • 整合重組免疫療法以降低HIV相關隱球菌腦膜炎的死亡率
  • 開發長效注射藥物以提高隱球菌病治療的依從性
  • 更重視全球衛生舉措，為撒哈拉以南非洲無症狀性隱球菌抗原血症篩檢計畫提供資金
  • 評估免疫療法與抗真菌療法聯合使用以縮短治療時間的臨床試驗
  • 實施人工智慧驅動的預測模型以最佳化隱球菌腦膜炎管理中的患者預後
  • Fluconazole非專利市場動態影響發展中國家和新興國家的藥品定價和取得途徑

第6章：2025年美國關稅的累積影響

第7章：人工智慧的累積影響，2025年

8. 隱球菌病市場（依藥物類別）

  • Azole
    • Fluconazole
    • Isavuconazole
    • Itraconazole
    • Posaconazole
    • Voriconazole
  • Echinocandins
    • 阿尼芬淨
    • Caspofungin
    • Micafungin
  • Polyenes
  • 嘧啶類似物

9. 隱球菌病市場（按適應症）

  • 隱球菌腦膜炎
  • 播散性隱球菌病
  • 肺隱球菌病

10. 依給藥途徑分類的隱球菌病市場

  • 靜脈
  • 口服

第 11 章。隱球菌病市場（按最終用戶）

  • 門診治療中心
  • 診所
  • 醫院

第 12 章。隱球菌病市場（按分銷管道）

  • 醫院藥房
  • 網路藥局
  • 零售藥局

13. 隱球菌病市場（按地區）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第 14 章。隱球菌病市場（按類別）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第 15 章。各國隱球菌病市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章競爭格局

  • 2024年市佔率分析
  • 2024年FPNV定位矩陣
  • 競爭分析
    • Gilead Sciences, Inc.
    • Viatris Inc.
    • Pfizer Inc.
    • Bausch Health Companies Inc.
    • Merck & Co., Inc.
    • Bristol-Myers Squibb Company
    • Johnson & Johnson
Product Code: MRR-4348D129F9A0

The Cryptococcosis Market is projected to grow by USD 11.66 billion at a CAGR of 7.87% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 6.35 billion
Estimated Year [2025] USD 6.87 billion
Forecast Year [2032] USD 11.66 billion
CAGR (%) 7.87%

An authoritative introduction to the clinical complexity, diagnostic challenges, therapeutic pathways, and system-level priorities shaping cryptococcosis care delivery

Cryptococcosis remains a complex invasive fungal disease that disproportionately affects immunocompromised populations and challenges health systems with diagnostic ambiguity and treatment complexity. Clinicians encounter a spectrum of presentations ranging from subacute pulmonary infection to life-threatening cryptococcal meningitis, and divergent patient pathways complicate timely intervention. Laboratory confirmation often requires culture, antigen testing, and neuroimaging, and delays in recognition contribute to morbidity and mortality despite the availability of antifungal agents with proven efficacy in controlled settings.

From the perspective of stakeholders across clinical care, pharmaceutical development, and health policy, cryptococcosis demands a nuanced understanding of therapeutic modalities, routes of administration, and care delivery environments. Treatment paradigms span intravenous induction therapies and oral consolidation and maintenance phases, which in turn create logistical burdens for hospital pharmacies, outpatient clinics, and ambulatory care centers. At the same time, disparities in access to diagnostics and antifungal agents persist across regions, exacerbating inequities in outcomes.

This executive introduction frames the subsequent analysis by outlining core clinical challenges, characterizing principal treatment classes, and signaling where innovation and operational change can materially improve patient trajectories. It sets the stage for a deeper exploration of transformative shifts, tariff-related pressures in the United States, segmentation-driven insights, regional nuances, corporate dynamics, and pragmatic recommendations for leaders navigating the cryptococcosis landscape.

How advances in diagnostics, therapeutic innovation, care delivery redesign, and stewardship initiatives are jointly transforming cryptococcosis management across care settings

The landscape of cryptococcosis is undergoing multiple simultaneous shifts that are reshaping how clinicians detect, manage, and prevent severe disease. Advances in rapid antigen testing and point-of-care diagnostics are enabling earlier identification of cryptococcal infection, which in turn supports more timely initiation of appropriate antifungal therapy and reduces reliance on prolonged empiric treatment. At the same time, improvements in imaging, molecular assays, and integrated electronic health records are facilitating earlier triage of patients at risk for central nervous system involvement.

Therapeutically, the field is seeing renewed attention to novel antifungal compounds, optimized dosing regimens, and adjunctive strategies that target host immune responses. These developments are being driven by translational research as well as by clinical practitioners seeking more tolerable and logistically feasible regimens, particularly those that reduce the need for prolonged inpatient intravenous therapy. Concurrently, rising antifungal resistance patterns and variability in drug availability are prompting stewardship initiatives and incentivizing investment in drug manufacturing resilience.

Health systems are also adapting operationally. Greater emphasis on outpatient infusion services, integration of clinic-based monitoring programs, and partnerships between hospitals and community providers are altering the care continuum. Payers and procurement teams are increasingly focused on total cost of care and patient-centered outcomes, encouraging interventions that shorten hospital lengths of stay and reduce readmissions. Taken together, these transformative shifts are repositioning therapeutic decision-making, supply chain design, and clinical practice guidelines across multiple care settings.

Assessing how recent tariff adjustments are reshaping pharmaceutical sourcing, supply chain resilience, procurement strategies, and access to critical antifungal therapies

The policy landscape in 2025 introduces consequential dynamics for cryptococcosis supply chains and procurement practices as tariff adjustments shape the economics of importing active pharmaceutical ingredients, finished formulations, and ancillary clinical supplies. Tariff increases on key inputs can raise landed costs for pharmaceutical manufacturers and contract formulators, creating downstream pressure on procurement teams in hospitals, clinics, and pharmacies that already operate under constrained budgets. In turn, higher acquisition costs may accelerate efforts to prioritize oral agents that are less dependent on complex sterile manufacturing or to shift purchasing toward suppliers with vertically integrated production to mitigate tariff exposure.

From an operational perspective, tariff-driven cost pressures can amplify supply chain fragility by incentivizing stockpiling of intravenous formulations, increasing reliance on domestic contract manufacturers, and prompting reconfiguration of distribution channels. Hospitals may respond by adapting formularies, negotiating extended supply agreements, and imposing stricter utilization controls to preserve access for high-risk patients. These responses will often intersect with regulatory requirements for sterile preparation and with clinical imperatives to maintain uninterrupted availability of induction therapies that are administered intravenously, which are less easily substituted than oral alternatives.

Regulatory and commercial actors are likely to pursue mitigations that preserve therapeutic continuity. Manufacturers may explore reformulation or alternative sourcing strategies for APIs, pursue tariff classification reviews, and expand regional manufacturing footprints to avoid tariff exposure. Payers and procurement professionals may place greater emphasis on value-based contracting and bundled purchasing arrangements to smooth price volatility. Health systems should anticipate procurement cycles that increasingly account for geopolitical risk and tariff regimes, and they should cultivate closer collaboration with supply partners to secure predictable access. In this environment, strategic planning that combines clinical prioritization with supply chain agility will be essential to safeguard patient care and manage cumulative tariff impacts effectively.

Segmentation-driven insights that align drug classes, clinical indications, administration routes, care settings, and distribution channels to prioritize interventions and optimize continuity of care

Segmentation provides a structured lens to evaluate therapeutic and operational priorities across cryptococcosis care pathways. Based on drug class, the landscape includes Azoles, Echinocandins, Polyenes, and Pyrimidine Analogues, with the Azoles further characterized by agents such as Fluconazole, Isavuconazole, Itraconazole, Posaconazole, and Voriconazole, and the Echinocandins exemplified by Anidulafungin, Caspofungin, and Micafungin; this diversity of antifungal mechanisms creates both clinical options and formulary complexity, demanding differentiated supply chain and stewardship approaches. Based on indication, clinical strategies vary across cryptococcal meningitis, disseminated cryptococcosis, and pulmonary cryptococcosis, each requiring distinct diagnostic pathways, intensity of monitoring, and duration of therapy that influence site-of-care decisions and resource allocation.

Variation by route of administration-intravenous versus oral-shapes operational considerations such as inpatient bed utilization, outpatient infusion capacity, and the importance of adherence support. Similarly, end-user segmentation across ambulatory care centers, clinics, and hospitals highlights where investments in point-of-care testing, infusion infrastructure, and clinician education will yield the greatest impact. Distribution channel segmentation that distinguishes hospital pharmacy, online pharmacy, and retail pharmacy underscores evolving procurement and access models; while hospital pharmacies manage acute inpatient supplies and sterile compounding, online and retail pharmacies play an increasing role in outpatient consolidation and maintenance phases, demanding interoperability between clinical prescribing workflows and dispensing logistics.

Synthesizing these segmentation dimensions clarifies where interventions can be prioritized to optimize outcomes. For example, alignment between drug class preferences and route-of-administration realities can reduce unnecessary inpatient occupancy, and coordination across end users and distribution channels can enhance continuity of care from induction to maintenance. This segmentation-driven perspective empowers stakeholders to target investments in diagnostics, formulary management, and supply chain redesign according to the clinical scenarios and delivery settings that matter most.

How regional healthcare infrastructure, regulatory frameworks, and manufacturing footprints shape access, treatment delivery, and strategic investments in cryptococcosis care

Regional dynamics materially influence clinical practice, access to antifungal agents, and the operational capacity to manage cryptococcosis. In the Americas, health systems span a broad spectrum of resources and infrastructure, with centers of excellence capable of advanced diagnostics and inpatient management juxtaposed against rural and underserved areas that face access barriers. This geographic heterogeneity necessitates regional strategies that combine centralized specialty care with decentralized diagnostic and outpatient management capabilities to ensure timely identification and treatment across diverse populations.

Across Europe, Middle East & Africa, differences in regulatory frameworks, procurement mechanisms, and manufacturing footprints create varying levels of access to essential antifungal agents and supportive care. In some countries, robust hospital-based systems can rapidly deploy intravenous induction therapy, while in others limited access to sterile compounding or to specific agents constrains treatment options. Consequently, regional policy coordination and capacity building for diagnostics and infusion services are critical to leveling outcomes across disparate healthcare environments.

In the Asia-Pacific region, high disease burden in certain jurisdictions intersects with rapidly evolving pharmaceutical manufacturing capacity and significant variations in reimbursement models. These dynamics create opportunities for innovative distribution approaches, public-private partnerships, and localized production that reduce dependence on long-distance supply chains. Across all regions, interoperability between clinical guidelines, procurement strategies, and supply chain planning remains a central enabler of equitable access to timely, guideline-concordant cryptococcosis care.

Key corporate strategies and partnership dynamics focused on therapeutic innovation, sterile manufacturing resilience, distribution diversification, and value-added patient services

Corporate strategies across the cryptococcosis ecosystem reflect a balance between innovation in therapeutic development and operational measures to secure reliable supply for existing antifungal agents. Pharmaceutical and biotech companies are focusing on pipeline maturation for novel compounds and formulation improvements that can reduce reliance on inpatient administration. At the same time, established manufacturers and generic producers are investing in sterile manufacturing capacity and quality systems to meet the demands of both induction and maintenance therapies.

Collaborations between clinical research institutions, contract manufacturers, and specialty distributors are becoming more common, facilitating faster translation of clinical data into accessible product offerings. Companies are also diversifying distribution networks to reduce single-source dependencies and to adapt to tariff or trade disruptions. Commercial teams are prioritizing engagement with hospital pharmacy directors and integrated care networks to ensure product availability aligns with clinical pathways and procurement cycles.

Beyond product availability, competitors are differentiating through service offerings such as patient support programs, adherence solutions for oral maintenance therapy, and education initiatives for clinicians managing complex cryptococcosis cases. These value-added services are designed to optimize patient outcomes while embedding therapies within coherent care pathways. Overall, corporate activity is converging on a dual objective: advancing therapeutic options that simplify clinical management and strengthening supply and commercial channels that secure consistent access across diverse care settings.

Actionable recommendations for manufacturers, providers, and payers to strengthen supply chain resilience, simplify therapy delivery, and align incentives with patient outcomes

Industry leaders can take practical steps to strengthen clinical outcomes and safeguard access to antifungal therapies by combining clinical, operational, and commercial levers. Manufacturers should prioritize investments in formulation research that enable more oral or simplified dosing regimens, while simultaneously expanding regional manufacturing and qualified supplier networks to reduce exposure to trade disruptions. This approach lessens dependence on single-source APIs and supports greater continuity in both intravenous and oral product availability.

Health systems and hospital pharmacies should formalize contingency procurement plans, including strategic inventory policies for induction agents and mechanisms for rapid substitution guided by clinical consensus. Strengthening partnerships with outpatient infusion providers and retail or online pharmacies will facilitate smoother care transitions from inpatient induction to outpatient maintenance. Moreover, clinical leaders should integrate rapid cryptococcal antigen testing into triage protocols and adopt standardized care bundles that ensure early initiation of appropriate therapy and consistent follow-up.

Payers and policymakers can enable these operational shifts by aligning reimbursement incentives with outcomes-based metrics that reward shorter hospital stays, reduced readmissions, and adherence to evidence-based treatment pathways. Cross-sector collaboration-bringing together manufacturers, payers, providers, and patient advocacy groups-will be essential to design realistic procurement frameworks, support education programs, and implement stewardship practices that preserve antifungal efficacy. By executing coordinated actions that target the supply chain, care delivery, and reimbursement architecture, industry leaders can materially improve access and outcomes for patients with cryptococcosis.

A rigorous mixed-methods research methodology integrating literature synthesis, expert interviews, procurement analytics, and scenario evaluation to generate actionable clinical and commercial insights

The research approach underpinning this analysis combined a structured review of primary and secondary information sources, expert consultations, and cross-validation of clinical and operational themes. Secondary research encompassed peer-reviewed literature, clinical practice guidelines, regulatory filings, and clinical trial registries to map therapeutic profiles, diagnostic modalities, and standard-of-care algorithms. These sources provided the clinical context necessary to interpret therapeutic mechanisms, safety considerations, and route-of-administration implications.

Primary research included structured interviews with clinicians treating cryptococcosis across inpatient and outpatient settings, hospital pharmacy leaders, procurement specialists, and industry executives responsible for manufacturing and distribution. These conversations yielded practical perspectives on supply chain risks, formulary decision drivers, and real-world challenges in delivering induction versus maintenance therapy. In addition, synthesis of de-identified hospital procurement patterns and diagnostic utilization metrics informed understanding of distribution channel dynamics and care setting pressures.

Data synthesis prioritized triangulation, ensuring that clinical findings were consistent with operational realities and supply chain constraints. Analytical techniques included thematic analysis of qualitative interviews, cross-mapping of therapeutic attributes to care settings, and scenario-based evaluation of policy shifts such as tariff changes. This mixed-methods approach produced a balanced, actionable set of insights while maintaining transparency about data sources and the assumptions guiding interpretive judgments.

A concise concluding synthesis highlighting the interdependence of diagnostics, therapeutic delivery, supply resilience, and aligned incentives to improve cryptococcosis outcomes

In conclusion, cryptococcosis presents a persistent clinical challenge that intersects with complex operational and commercial considerations. Clinicians, manufacturers, and health system leaders must navigate diagnostic variability, regimen complexity, and evolving policy environments while preserving timely access to both intravenous induction agents and oral maintenance therapies. Strategic responses that combine diagnostic acceleration, therapeutic simplification, and supply chain diversification will be essential to improve outcomes and protect against disruption.

The interplay between therapeutic segmentation, care setting dynamics, and regional infrastructure underscores the need for tailored interventions that reflect local realities. Investment in point-of-care diagnostics, outpatient infusion capacity, and manufacturing redundancy will yield disproportionate benefits by facilitating guideline-concordant care and reducing preventable complications. Equally important is the alignment of commercial and reimbursement models with clinical goals to incentivize high-value care.

Ultimately, stakeholders who proactively redesign care pathways, strengthen supplier relationships, and pursue evidence-based innovations will be best positioned to reduce clinical burden and ensure sustainable access to antifungal therapies. This report's insights are intended to inform those strategic choices and to provide a practical roadmap for translating clinical evidence into operational action.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Expansion of next-generation antifungal therapies targeting resistant cryptococcus strains
  • 5.2. Adoption of rapid point-of-care diagnostic assays for early cryptococcal antigen detection in resource-limited regions
  • 5.3. Integration of recombinant immune-based treatments to reduce mortality in HIV-associated cryptococcal meningitis
  • 5.4. Development of long-acting injectable formulations to improve adherence in cryptococcosis therapy
  • 5.5. Rising focus on global health initiatives funding screening programs for asymptomatic cryptococcal antigenemia in sub-Saharan Africa
  • 5.6. Clinical trials evaluating combination immunotherapy and antifungal regimens to shorten treatment duration in cryptococcosis
  • 5.7. Implementation of AI-driven predictive modeling for patient outcome optimization in cryptococcal meningitis management
  • 5.8. Emergence of generic fluconazole market dynamics influencing drug pricing and access in developing countries

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Cryptococcosis Market, by Drug Class

  • 8.1. Azoles
    • 8.1.1. Fluconazole
    • 8.1.2. Isavuconazole
    • 8.1.3. Itraconazole
    • 8.1.4. Posaconazole
    • 8.1.5. Voriconazole
  • 8.2. Echinocandins
    • 8.2.1. Anidulafungin
    • 8.2.2. Caspofungin
    • 8.2.3. Micafungin
  • 8.3. Polyenes
  • 8.4. Pyrimidine Analogues

9. Cryptococcosis Market, by Indication

  • 9.1. Cryptococcal Meningitis
  • 9.2. Disseminated Cryptococcosis
  • 9.3. Pulmonary Cryptococcosis

10. Cryptococcosis Market, by Route Of Administration

  • 10.1. Intravenous
  • 10.2. Oral

11. Cryptococcosis Market, by End User

  • 11.1. Ambulatory Care Center
  • 11.2. Clinic
  • 11.3. Hospital

12. Cryptococcosis Market, by Distribution Channel

  • 12.1. Hospital Pharmacy
  • 12.2. Online Pharmacy
  • 12.3. Retail Pharmacy

13. Cryptococcosis Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Cryptococcosis Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Cryptococcosis Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. Gilead Sciences, Inc.
    • 16.3.2. Viatris Inc.
    • 16.3.3. Pfizer Inc.
    • 16.3.4. Bausch Health Companies Inc.
    • 16.3.5. Merck & Co., Inc.
    • 16.3.6. Bristol-Myers Squibb Company
    • 16.3.7. Johnson & Johnson

LIST OF FIGURES

  • FIGURE 1. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY DRUG CLASS, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY INDICATION, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS CRYPTOCOCCOSIS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA CRYPTOCOCCOSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA CRYPTOCOCCOSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA CRYPTOCOCCOSIS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE CRYPTOCOCCOSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST CRYPTOCOCCOSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA CRYPTOCOCCOSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC CRYPTOCOCCOSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN CRYPTOCOCCOSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC CRYPTOCOCCOSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION CRYPTOCOCCOSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS CRYPTOCOCCOSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 CRYPTOCOCCOSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO CRYPTOCOCCOSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. CRYPTOCOCCOSIS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. CRYPTOCOCCOSIS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. CRYPTOCOCCOSIS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY AZOLES, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY AZOLES, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY AZOLES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY AZOLES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY AZOLES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY AZOLES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY AZOLES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY AZOLES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY FLUCONAZOLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY FLUCONAZOLE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY FLUCONAZOLE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY FLUCONAZOLE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY FLUCONAZOLE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY FLUCONAZOLE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY ISAVUCONAZOLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY ISAVUCONAZOLE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY ISAVUCONAZOLE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY ISAVUCONAZOLE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY ISAVUCONAZOLE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY ISAVUCONAZOLE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY ITRACONAZOLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY ITRACONAZOLE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY ITRACONAZOLE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY ITRACONAZOLE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY ITRACONAZOLE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY ITRACONAZOLE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY POSACONAZOLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY POSACONAZOLE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY POSACONAZOLE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY POSACONAZOLE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY POSACONAZOLE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY POSACONAZOLE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY VORICONAZOLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY VORICONAZOLE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY VORICONAZOLE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY VORICONAZOLE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY VORICONAZOLE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY VORICONAZOLE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY ECHINOCANDINS, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY ECHINOCANDINS, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY ECHINOCANDINS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY ECHINOCANDINS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY ECHINOCANDINS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY ECHINOCANDINS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY ECHINOCANDINS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY ECHINOCANDINS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY ANIDULAFUNGIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY ANIDULAFUNGIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY ANIDULAFUNGIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY ANIDULAFUNGIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY ANIDULAFUNGIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY ANIDULAFUNGIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY CASPOFUNGIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY CASPOFUNGIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY CASPOFUNGIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY CASPOFUNGIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY CASPOFUNGIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY CASPOFUNGIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY MICAFUNGIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY MICAFUNGIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY MICAFUNGIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY MICAFUNGIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY MICAFUNGIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY MICAFUNGIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY POLYENES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY POLYENES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY POLYENES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY POLYENES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY POLYENES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY POLYENES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY PYRIMIDINE ANALOGUES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY PYRIMIDINE ANALOGUES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY PYRIMIDINE ANALOGUES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY PYRIMIDINE ANALOGUES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY PYRIMIDINE ANALOGUES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY PYRIMIDINE ANALOGUES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY CRYPTOCOCCAL MENINGITIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY CRYPTOCOCCAL MENINGITIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY CRYPTOCOCCAL MENINGITIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY CRYPTOCOCCAL MENINGITIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY CRYPTOCOCCAL MENINGITIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY CRYPTOCOCCAL MENINGITIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY DISSEMINATED CRYPTOCOCCOSIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY DISSEMINATED CRYPTOCOCCOSIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY DISSEMINATED CRYPTOCOCCOSIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY DISSEMINATED CRYPTOCOCCOSIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY DISSEMINATED CRYPTOCOCCOSIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY DISSEMINATED CRYPTOCOCCOSIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY PULMONARY CRYPTOCOCCOSIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY PULMONARY CRYPTOCOCCOSIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY PULMONARY CRYPTOCOCCOSIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY PULMONARY CRYPTOCOCCOSIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY PULMONARY CRYPTOCOCCOSIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY PULMONARY CRYPTOCOCCOSIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY AMBULATORY CARE CENTER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY AMBULATORY CARE CENTER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY AMBULATORY CARE CENTER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY AMBULATORY CARE CENTER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY AMBULATORY CARE CENTER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY AMBULATORY CARE CENTER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY CLINIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY CLINIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY CLINIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY CLINIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY CLINIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY CLINIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY HOSPITAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY HOSPITAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY HOSPITAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY HOSPITAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY HOSPITAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 159. AMERICAS CRYPTOCOCCOSIS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 160. AMERICAS CRYPTOCOCCOSIS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 161. AMERICAS CRYPTOCOCCOSIS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 162. AMERICAS CRYPTOCOCCOSIS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 163. AMERICAS CRYPTOCOCCOSIS MARKET SIZE, BY AZOLES, 2018-2024 (USD MILLION)
  • TABLE 164. AMERICAS CRYPTOCOCCOSIS MARKET SIZE, BY AZOLES, 2025-2032 (USD MILLION)
  • TABLE 165. AMERICAS CRYPTOCOCCOSIS MARKET SIZE, BY ECHINOCANDINS, 2018-2024 (USD MILLION)
  • TABLE 166. AMERICAS CRYPTOCOCCOSIS MARKET SIZE, BY ECHINOCANDINS, 2025-2032 (USD MILLION)
  • TABLE 167. AMERICAS CRYPTOCOCCOSIS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 168. AMERICAS CRYPTOCOCCOSIS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 169. AMERICAS CRYPTOCOCCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 170. AMERICAS CRYPTOCOCCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 171. AMERICAS CRYPTOCOCCOSIS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 172. AMERICAS CRYPTOCOCCOSIS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 173. AMERICAS CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 174. AMERICAS CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 175. NORTH AMERICA CRYPTOCOCCOSIS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 176. NORTH AMERICA CRYPTOCOCCOSIS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 177. NORTH AMERICA CRYPTOCOCCOSIS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 178. NORTH AMERICA CRYPTOCOCCOSIS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 179. NORTH AMERICA CRYPTOCOCCOSIS MARKET SIZE, BY AZOLES, 2018-2024 (USD MILLION)
  • TABLE 180. NORTH AMERICA CRYPTOCOCCOSIS MARKET SIZE, BY AZOLES, 2025-2032 (USD MILLION)
  • TABLE 181. NORTH AMERICA CRYPTOCOCCOSIS MARKET SIZE, BY ECHINOCANDINS, 2018-2024 (USD MILLION)
  • TABLE 182. NORTH AMERICA CRYPTOCOCCOSIS MARKET SIZE, BY ECHINOCANDINS, 2025-2032 (USD MILLION)
  • TABLE 183. NORTH AMERICA CRYPTOCOCCOSIS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 184. NORTH AMERICA CRYPTOCOCCOSIS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 185. NORTH AMERICA CRYPTOCOCCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 186. NORTH AMERICA CRYPTOCOCCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 187. NORTH AMERICA CRYPTOCOCCOSIS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 188. NORTH AMERICA CRYPTOCOCCOSIS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 189. NORTH AMERICA CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 190. NORTH AMERICA CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 191. LATIN AMERICA CRYPTOCOCCOSIS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 192. LATIN AMERICA CRYPTOCOCCOSIS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 193. LATIN AMERICA CRYPTOCOCCOSIS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 194. LATIN AMERICA CRYPTOCOCCOSIS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 195. LATIN AMERICA CRYPTOCOCCOSIS MARKET SIZE, BY AZOLES, 2018-2024 (USD MILLION)
  • TABLE 196. LATIN AMERICA CRYPTOCOCCOSIS MARKET SIZE, BY AZOLES, 2025-2032 (USD MILLION)
  • TABLE 197. LATIN AMERICA CRYPTOCOCCOSIS MARKET SIZE, BY ECHINOCANDINS, 2018-2024 (USD MILLION)
  • TABLE 198. LATIN AMERICA CRYPTOCOCCOSIS MARKET SIZE, BY ECHINOCANDINS, 2025-2032 (USD MILLION)
  • TABLE 199. LATIN AMERICA CRYPTOCOCCOSIS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 200. LATIN AMERICA CRYPTOCOCCOSIS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 201. LATIN AMERICA CRYPTOCOCCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 202. LATIN AMERICA CRYPTOCOCCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 203. LATIN AMERICA CRYPTOCOCCOSIS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 204. LATIN AMERICA CRYPTOCOCCOSIS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 205. LATIN AMERICA CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 206. LATIN AMERICA CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 207. EUROPE, MIDDLE EAST & AFRICA CRYPTOCOCCOSIS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 208. EUROPE, MIDDLE EAST & AFRICA CRYPTOCOCCOSIS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 209. EUROPE, MIDDLE EAST & AFRICA CRYPTOCOCCOSIS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 210. EUROPE, MIDDLE EAST & AFRICA CRYPTOCOCCOSIS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 211. EUROPE, MIDDLE EAST & AFRICA CRYPTOCOCCOSIS MARKET SIZE, BY AZOLES, 2018-2024 (USD MILLION)
  • TABLE 212. EUROPE, MIDDLE EAST & AFRICA CRYPTOCOCCOSIS MARKET SIZE, BY AZOLES, 2025-2032 (USD MILLION)
  • TABLE 213. EUROPE, MIDDLE EAST & AFRICA CRYPTOCOCCOSIS MARKET SIZE, BY ECHINOCANDINS, 2018-2024 (USD MILLION)
  • TABLE 214. EUROPE, MIDDLE EAST & AFRICA CRYPTOCOCCOSIS MARKET SIZE, BY ECHINOCANDINS, 2025-2032 (USD MILLION)
  • TABLE 215. EUROPE, MIDDLE EAST & AFRICA CRYPTOCOCCOSIS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 216. EUROPE, MIDDLE EAST & AFRICA CRYPTOCOCCOSIS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 217. EUROPE, MIDDLE EAST & AFRICA CRYPTOCOCCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 218. EUROPE, MIDDLE EAST & AFRICA CRYPTOCOCCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 219. EUROPE, MIDDLE EAST & AFRICA CRYPTOCOCCOSIS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 220. EUROPE, MIDDLE EAST & AFRICA CRYPTOCOCCOSIS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 221. EUROPE, MIDDLE EAST & AFRICA CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 222. EUROPE, MIDDLE EAST & AFRICA CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 223. EUROPE CRYPTOCOCCOSIS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 224. EUROPE CRYPTOCOCCOSIS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 225. EUROPE CRYPTOCOCCOSIS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 226. EUROPE CRYPTOCOCCOSIS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 227. EUROPE CRYPTOCOCCOSIS MARKET SIZE, BY AZOLES, 2018-2024 (USD MILLION)
  • TABLE 228. EUROPE CRYPTOCOCCOSIS MARKET SIZE, BY AZOLES, 2025-2032 (USD MILLION)
  • TABLE 229. EUROPE CRYPTOCOCCOSIS MARKET SIZE, BY ECHINOCANDINS, 2018-2024 (USD MILLION)
  • TABLE 230. EUROPE CRYPTOCOCCOSIS MARKET SIZE, BY ECHINOCANDINS, 2025-2032 (USD MILLION)
  • TABLE 231. EUROPE CRYPTOCOCCOSIS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 232. EUROPE CRYPTOCOCCOSIS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 233. EUROPE CRYPTOCOCCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 234. EUROPE CRYPTOCOCCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 235. EUROPE CRYPTOCOCCOSIS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 236. EUROPE CRYPTOCOCCOSIS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 237. EUROPE CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 238. EUROPE CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 239. MIDDLE EAST CRYPTOCOCCOSIS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 240. MIDDLE EAST CRYPTOCOCCOSIS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 241. MIDDLE EAST CRYPTOCOCCOSIS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 242. MIDDLE EAST CRYPTOCOCCOSIS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 243. MIDDLE EAST CRYPTOCOCCOSIS MARKET SIZE, BY AZOLES, 2018-2024 (USD MILLION)
  • TABLE 244. MIDDLE EAST CRYPTOCOCCOSIS MARKET SIZE, BY AZOLES, 2025-2032 (USD MILLION)
  • TABLE 245. MIDDLE EAST CRYPTOCOCCOSIS MARKET SIZE, BY ECHINOCANDINS, 2018-2024 (USD MILLION)
  • TABLE 246. MIDDLE EAST CRYPTOCOCCOSIS MARKET SIZE, BY ECHINOCANDINS, 2025-2032 (USD MILLION)
  • TABLE 247. MIDDLE EAST CRYPTOCOCCOSIS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 248. MIDDLE EAST CRYPTOCOCCOSIS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 249. MIDDLE EAST CRYPTOCOCCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 250. MIDDLE EAST CRYPTOCOCCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 251. MIDDLE EAST CRYPTOCOCCOSIS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 252. MIDDLE EAST CRYPTOCOCCOSIS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 253. MIDDLE EAST CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 254. MIDDLE EAST CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 255. AFRICA CRYPTOCOCCOSIS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 256. AFRICA CRYPTOCOCCOSIS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 257. AFRICA CRYPTOCOCCOSIS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 258. AFRICA CRYPTOCOCCOSIS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 259. AFRICA CRYPTOCOCCOSIS MARKET SIZE, BY AZOLES, 2018-2024 (USD MILLION)
  • TABLE 260. AFRICA CRYPTOCOCCOSIS MARKET SIZE, BY AZOLES, 2025-2032 (USD MILLION)
  • TABLE 261. AFRICA CRYPTOCOCCOSIS MARKET SIZE, BY ECHINOCANDINS, 2018-2024 (USD MILLION)
  • TABLE 262. AFRICA CRYPTOCOCCOSIS MARKET SIZE, BY ECHINOCANDINS, 2025-2032 (USD MILLION)
  • TABLE 263. AFRICA CRYPTOCOCCOSIS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 264. AFRICA CRYPTOCOCCOSIS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 265. AFRICA CRYPTOCOCCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 266. AFRICA CRYPTOCOCCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 267. AFRICA CRYPTOCOCCOSIS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 268. AFRICA CRYPTOCOCCOSIS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 269. AFRICA CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 270. AFRICA CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 271. ASIA-PACIFIC CRYPTOCOCCOSIS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 272. ASIA-PACIFIC CRYPTOCOCCOSIS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 273. ASIA-PACIFIC CRYPTOCOCCOSIS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 274. ASIA-PACIFIC CRYPTOCOCCOSIS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 275. ASIA-PACIFIC CRYPTOCOCCOSIS MARKET SIZE, BY AZOLES, 2018-2024 (USD MILLION)
  • TABLE 276. ASIA-PACIFIC CRYPTOCOCCOSIS MARKET SIZE, BY AZOLES, 2025-2032 (USD MILLION)
  • TABLE 277. ASIA-PACIFIC CRYPTOCOCCOSIS MARKET SIZE, BY ECHINOCANDINS, 2018-2024 (USD MILLION)
  • TABLE 278. ASIA-PACIFIC CRYPTOCOCCOSIS MARKET SIZE, BY ECHINOCANDINS, 2025-2032 (USD MILLION)
  • TABLE 279. ASIA-PACIFIC CRYPTOCOCCOSIS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 280. ASIA-PACIFIC CRYPTOCOCCOSIS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 281. ASIA-PACIFIC CRYPTOCOCCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 282. ASIA-PACIFIC CRYPTOCOCCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 283. ASIA-PACIFIC CRYPTOCOCCOSIS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 284. ASIA-PACIFIC CRYPTOCOCCOSIS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 285. ASIA-PACIFIC CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 286. ASIA-PACIFIC CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 287. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 288. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 289. ASEAN CRYPTOCOCCOSIS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 290. ASEAN CRYPTOCOCCOSIS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 291. ASEAN CRYPTOCOCCOSIS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 292. ASEAN CRYPTOCOCCOSIS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 293. ASEAN CRYPTOCOCCOSIS MARKET SIZE, BY AZOLES, 2018-2024 (USD MILLION)
  • TABLE 294. ASEAN CRYPTOCOCCOSIS MARKET SIZE, BY AZOLES, 2025-2032 (USD MILLION)
  • TABLE 295. ASEAN CRYPTOCOCCOSIS MARKET SIZE, BY ECHINOCANDINS, 2018-2024 (USD MILLION)
  • TABLE 296. ASEAN CRYPTOCOCCOSIS MARKET SIZE, BY ECHINOCANDINS, 2025-2032 (USD MILLION)
  • TABLE 297. ASEAN CRYPTOCOCCOSIS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 298. ASEAN CRYPTOCOCCOSIS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 299. ASEAN CRYPTOCOCCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 300. ASEAN CRYPTOCOCCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 301. ASEAN CRYPTOCOCCOSIS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 302. ASEAN CRYPTOCOCCOSIS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 303. ASEAN CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 304. ASEAN CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 305. GCC CRYPTOCOCCOSIS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 306. GCC CRYPTOCOCCOSIS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 307. GCC CRYPTOCOCCOSIS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 308. GCC CRYPTOCOCCOSIS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 309. GCC CRYPTOCOCCOSIS MARKET SIZE, BY AZOLES, 2018-2024 (USD MILLION)
  • TABLE 310. GCC CRYPTOCOCCOSIS MARKET SIZE, BY AZOLES, 2025-2032 (USD MILLION)
  • TABLE 311. GCC CRYPTOCOCCOSIS MARKET SIZE, BY ECHINOCANDINS, 2018-2024 (USD MILLION)
  • TABLE 312. GCC CRYPTOCOCCOSIS MARKET SIZE, BY ECHINOCANDINS, 2025-2032 (USD MILLION)
  • TABLE 313. GCC CRYPTOCOCCOSIS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 314. GCC CRYPTOCOCCOSIS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 315. GCC CRYPTOCOCCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 316. GCC CRYPTOCOCCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 317. GCC CRYPTOCOCCOSIS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 318. GCC CRYPTOCOCCOSIS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 319. GCC CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 320. GCC CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 321. EUROPEAN UNION CRYPTOCOCCOSIS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 322. EUROPEAN UNION CRYPTOCOCCOSIS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 323. EUROPEAN UNION CRYPTOCOCCOSIS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 324. EUROPEAN UNION CRYPTOCOCCOSIS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 325. EUROPEAN UNION CRYPTOCOCCOSIS MARKET SIZE, BY AZOLES, 2018-2024 (USD MILLION)
  • TABLE 326. EUROPEAN UNION CRYPTOCOCCOSIS MARKET SIZE, BY AZOLES, 2025-2032 (USD MILLION)
  • TABLE 327. EUROPEAN UNION CRYPTOCOCCOSIS MARKET SIZE, BY ECHINOCANDINS, 2018-2024 (USD MILLION)
  • TABLE 328. EUROPEAN UNION CRYPTOCOCCOSIS MARKET SIZE, BY ECHINOCANDINS, 2025-2032 (USD MILLION)
  • TABLE 329. EUROPEAN UNION CRYPTOCOCCOSIS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 330. EUROPEAN UNION CRYPTOCOCCOSIS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 331. EUROPEAN UNION CRYPTOCOCCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 332. EUROPEAN UNION CRYPTOCOCCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 333. EUROPEAN UNION CRYPTOCOCCOSIS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 334. EUROPEAN UNION CRYPTOCOCCOSIS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 335. EUROPEAN UNION CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 336. EUROPEAN UNION CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 337. BRICS CRYPTOCOCCOSIS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 338. BRICS CRYPTOCOCCOSIS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 339. BRICS CRYPTOCOCCOSIS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 340. BRICS CRYPTOCOCCOSIS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 341. BRICS CRYPTOCOCCOSIS MARKET SIZE, BY AZOLES, 2018-2024 (USD MILLION)
  • TABLE 342. BRICS CRYPTOCOCCOSIS MARKET SIZE, BY AZOLES, 2025-2032 (USD MILLION)
  • TABLE 343. BRICS CRYPTOCOCCOSIS MARKET SIZE, BY ECHINOCANDINS, 2018-2024 (USD MILLION)
  • TABLE 344. BRICS CRYPTOCOCCOSIS MARKET SIZE, BY ECHINOCANDINS, 2025-2032 (USD MILLION)
  • TABLE 345. BRICS CRYPTOCOCCOSIS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 346. BRICS CRYPTOCOCCOSIS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 347. BRICS CRYPTOCOCCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 348. BRICS CRYPTOCOCCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 349. BRICS CRYPTOCOCCOSIS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 350. BRICS CRYPTO